3 October 2002

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

DM 6884

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/535, 9/20, 9/48, 47/36

A1

(11) International Publication Number: WO 99/51239

(43) International Publication Date: 14 October 1999 (14.10.99)

(21) International Application Number: PCT/US99/07228

(22) International Filing Date: 1 April 1999 (01.04.99)

(30) Priority Data:
60/080,925 7 April 1998 (07.04.98) US

(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US).

(72) Inventors: MAKOOI-MOREHEAD, William, T.; 1 Virginia Lane, Wallingford, PA 19086 (US). BUEHLER, John, D.; 1111 Hunt Seat Drive, Ambler, PA 19002 (US). LANDMANN, Brian, R.; Apartment A, 220 Willow, Hoboken, NJ 07030 (US).

(74) Agent: VANCE, David, H.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FORMULATION OF FAST-DISSOLVING EFAVIRENZ CAPSULES OR TABLETS USING SUPER-DISINTEGRANTS

(57) Abstract

The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.

162162

G00002